The Board granted a disability rating of 30 percent, but no higher, for bilateral pes planus and plantar fasciitis based on the evidence showing that the Veteran's condition more closely approximated the schedular criteria for this rating.
The deciding factor: The VA clinicians reported objective evidence of marked deformity, pain on manipulation and use, indication of swelling on use, characteristic calluses, and marked pronation and extreme tenderness improved by orthopedic shoes or appliances, which supported a 30 percent rating under the applicable criteria.
- Claimed conditions
- Bilateral pes planus, Plantar fasciitis
- How they argued it
- Direct service connection
- Exposure basis
- None
- Rating assigned
- 30%
- Decision date
- July 3, 2025
- Citation
- A25057469
What this means for you
A grant means the Board agreed the veteran was entitled to the benefit. Decisions like this show the kind of evidence and arguments that tend to succeed for claims like it.
What you can do next
Related decisions
Other Board decisions on a similar condition or argued the same way.
- Granted
The Board granted earlier effective dates of November 5, 2021, for the grants of service connection and eligibility for DEA benefits.
- Denied
The Board denied an initial rating greater than 30 percent for plantar fasciitis as the evidence did not support a higher rating.
- Dismissed
The appeal was denied due to the untimely filing of the Board Appeal request.
- Dismissed
The appeal was dismissed due to untimely filing of the Notice of Disagreement (NOD) for claims related to an increased rating and service connection, as well as lack of jurisdiction over a previously granted claim for sinusitis.
We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.
This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.